Breath Therapeutics' lead program, BOSTON, develops the first therapy for the treatment of Bronchiolitis Obliterans Syndrome (BOS), which is a life-threatening disease where the immune system attacks the airways of the lungs.
- BOS is the result of a injury, some known and some unknown, that progresses even when the injury is removed.
- Histopathology of airways affected by BOS show a T-cell mediated inflammatory process that results in fibrous scarring of the respiratory bronchioles.
BOS is devastating to lung transplant and allogeneic stem cell recipients. There is no known therapy.
- BOS is irreversible and rapidly progressive. Mostly it leads to respiratory failure and death within 9-24 months after diagnosis.
- BOS is the leading cause of death following lung transplantation. Half of all lung transplant recipients die within 5 years and BOS is the #1 reason.
Liposomal Cyclosporine A (L-CsA) for inhalation targets the site of BOS-related airway inflammation.
- Proprietary drug formulation
- High topical drug concentrations at the site of action with without increasing systemic toxicity
- Orphan Drug Designation (FDA and EMA)
- PARI Investigational eFlow® nebulizer system for L-CsA with world-wide exclusive rights
- Multiple layers of IP protection for drug & device